Lecanemab’s PDUFA date for its potential accelerated approval is January 6th. The product could launch after its FDA approval. Now the discussion turns to what price it will be launched at, and whether it will eventually be reimbursed by CMS, the predominant payer for a product such as lecanemab.
Subscribe to:
Post Comments (Atom)
< + > Survey from Omega Systems Should Spur Investment in Healthcare Security
In an industry where more than 50% of leaders consider it “inevitable” for a cyberattack to result someday in a patient fatality, cybersecur...
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
-
Robert Connely of Pega says patching legacy systems will give way to true health IT modernization, a security breakthrough will lead artific...
No comments:
Post a Comment